The University of Texas at Dallas Student Health Center requires all persons born outside the United States to have an IGRA blood test (QuantiFERON or T-Spot) for TB screening to rule out TB, prior to registering for classes their first semester at UT Dallas. The student is responsible for having the required testing and for any related costs. Screening for TB must be administered and interpreted in the United States, regardless of prior BCG vaccination, within six (6) months of registration. You may mail, fax or email the completed form (allow sufficient time), or you may bring it with you and submit to the Student Health Center. Students who do not complete the screening for tuberculosis, an IGRA blood test, will not be allowed to register for classes.

Student Health Center
THE UNIVERSITY OF TEXAS AT DALLAS
800 W. Campbell Road SSB 43
Richardson, Texas 75080
(TEL) 972-883-2747
(FAX) 972-883-2069

Name (Please Print): ___________________________________ Date of Birth: MM/DD/YYYY
U.S. Address: _________________________________________ U.S. Phone #: ________________
Email Address: ___________________________ Student ID#: ______________________

Part I: Tuberculosis (TB) Screening Questionnaire (to be completed by incoming students)

Please answer the following questions:

Have you ever had close contact with persons known or suspected to have active TB disease? ☐ Yes ☐ No

Were you born in one of the countries or territories listed below that have a high incidence of active TB disease? (If yes, please CIRCLE the country, below)

Afghanistan, Algeria, Angola, Anguilla, Argentina, Armenia, Azerbaijan, Bangladesh, Belarus, Belize, Benin, Bhutan, Bolivia (Plurinational State of), Bosnia and Herzegovina, Botswana, Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cabo Verde, Cambodia, Cameroon, Central African Republic, Chad, China, China, Hong Kong SAR, China, Macao SAR, Colombia, Comoros, Congo, Côte d’Ivoire, Democratic People’s Republic of Korea, Democratic Republic of the Congo, Djibouti, Dominican Republic, Equatorial Guinea, Eritrea, Ethiopia, Fiji, Gabon, Gambia, Georgia, Ghana, Greenland, Guam, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, India, Indonesia, Iraq, Kazakhstan, Kenya, Kiribati, Kuwait, Kyrgyzstan, Lao People’s Democratic Republic, Latvia, Lesotho, Liberia, Libya, Lithuania, Madagascar, Malawi, Malaysia, Maldives, Mali, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia (Federated States of), Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, New Caledonia, Nicaragua, Niger, Nigeria, Northern Mariana Islands, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Portugal, Qatar, Republic of Korea, Republic of Moldova, Romania, Russian Federation, Rwanda, Sao Tome and Principe, Senegal, Serbia, Sierra Leone, Singapore, Solomon Islands, Somalia, South Africa, South Sudan, Sri Lanka, Sudan, Suriname, Swaziland, Syrian Arab Republic, Tajikistan, Tanzania (United Republic of), Thailand, Timor-Leste, Togo, Tunisia, Turkmenistan, Tuvalu, Uganda, Ukraine, Uruguay, Uzbekistan, Vanuatu, Venezuela (Bolivarian Republic of), Viet Nam, Yemen, Zambia, Zimbabwe

Have you had frequent or prolonged visits* to one or more of the countries or territories listed above with a high prevalence of TB disease? (If yes, CHECK the countries or territories, above)  

Have you been a resident and/or employee of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)?  

Have you been a volunteer or health care worker who served clients who are at increased risk for active TB disease?  

Have you ever been a member of any of the following groups that may have an increased incidence of latent *M. tuberculosis* infection or active TB disease: medically underserved, low-income, or abusing drugs or alcohol?  

* The significance of the travel exposure should be discussed with a health care provider and evaluated.

Interferon Gamma Release Assay (MUST PROVIDE COPY OF LAB REPORT)

a. Date Obtained: ____/____/____  (specify method)  QFT-GIT  T-Spot  other____
   M  D  Y
   Result:  negative___  positive___  indeterminate___  borderline___ (T-Spot only)

b. Date Obtained: ____/____/____  (specify method)  QFT-GIT  T-Spot  other____
   M  D  Y
   Result:  negative___  positive___  indeterminate___  borderline___ (T-Spot only)

Signature of Licensed Medical Provider ___________________________________________________

Name and Address of Provider or Clinic___________________________________________________

Phone Number________________________________________________________ Facility Stamp

**TO BE COMPLETED BY CLINICIAN ONLY IF IGRA IS POSITIVE**

**Part II. Clinical Assessment by Health Care Provider**

(Clinicians should review and verify the information in Part I)

History of a positive TB skin test or IGRA blood test? (If yes, document below)  Yes _____ No __

History of BCG vaccination?  Yes _____ No __

1. TB Symptom Check

Does the student have signs or symptoms of active pulmonary tuberculosis disease?  Yes _____ No __

If No, proceed to 2.

If yes, check below:

☐ Cough (especially if lasting for 3 weeks or longer) with or without sputum production
☐ Coughing up blood (hemoptysis)
☐ Chest pain
☐ Loss of appetite
☐ Unexplained weight loss
☐ Night sweats
☐ Fever
Proceed with additional evaluation to exclude active tuberculosis disease including tuberculin testing, chest x-ray, and sputum evaluation as indicated.

* The significance of the travel exposure should be discussed with a health care provider and evaluated.

2. Chest x-ray (Required if TST or IGRA is positive)

*Please provide a copy of the radiology report if available*

Date of chest x-ray: ____/____/____  Result: normal_____ abnormal_____

Reading – results of X-ray:

Signature of Radiologist or Ordering Physician:

Name of Facility where X-ray was taken: __________________________________________________________________________________________

Address: __________________________________________________________________________________________

**TO BE COMPLETED BY CLINICIAN ONLY IF EVALUATING FOR TB/LTBI**

Part III. Management of Positive TST or IGRA

All students with a positive TST or IGRA with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.

- Infected with HIV
- Recently infected with *M. tuberculosis* (within the past 2 years)
- History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
- Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
- Have had a gastrectomy or jejunoileal bypass
- Weigh less than 90% of their ideal body weight
- Cigarette smokers and persons who abuse drugs and/or alcohol

____ Student agrees to receive treatment
____ Student declines treatment at this time

_________________________________________________________          _____

Student Signature                          Date

_________________________________________________________          _____

Health Care Professional Signature        Date

Prepared originally by ACHA’s Tuberculosis Guidelines Task Force
Revised by Emerging Public Health Threats and Emergency Response Coalition

NOTE: Any student submitting false or fraudulent information will be subject to disciplinary action.

The University of Texas at Dallas Is an Equal Opportunity/ Affirmative Action University

June 2017